Silver linings on the horizon: highlights from the 10th Cachexia Conference

Journal of Cachexia, Sarcopenia and Muscle

Volumn 9, Issue 1, 2018, Pages 176-182

  Ebner, Nicole ^a   von Haehling, Stephan ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Cachexia; Muscle wasting; Sarcopenia

Indexed keywords

CREATINE; ELAMIPRETIDE; ENOBOSARM; MICRORNA; PROTEASOME; UBIQUITIN;

BODY COMPOSITION; CACHEXIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG TARGETING; HUMAN; MOLECULAR DIAGNOSIS; MTOR SIGNALING; MULTICENTER STUDY (TOPIC); MUSCLE ATROPHY; MUSCULAR DYSTROPHY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENCE; SKELETAL MUSCLE; SURVIVAL RATE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; SARCOPENIA;

CACHEXIA; HUMANS; SARCOPENIA;

EID: 85041739388     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12290     Document Type: Conference Paper

References (50)

1. Ebner N, Werner CG, Doehner W, Anker SD, von Haehling S. Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference. J Cachexia Sarcopenia Muscle 2012;3:45–50.
2. Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle 2014;5:27–34.
3. Ebner N, von Haehling S. Unlocking the wasting enigma: highlights from the 8th Cachexia Conference. J Cachexia Sarcopenia Muscle 2016;7:90–94.
4. Ebner N, von Haehling S. Highlights from the 9th Cachexia Conference. J Cachexia Sarcopenia Muscle 2017;8:508–511.
5. Ebner N, Springer J, Kalantar-Zadeh K, Lainscak M, Doehner W, Anker SD, von Haehling S. Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas 2013;75:199–206.
6. Plas RLC, Hooiveld GJEJ, Witkamp RF, van Norren K. Comparison of whole genome gene expression in (cancer) cachectic muscles of animal models and human patients. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 5–04.
7. Bhatt B, Narasimhan A, Bathe O, Baracos VE, Damaraju S. Long non-coding RNA profiling in human skeletal muscle and their role in Cancer Cachexia. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 4–07.
8. Barreto R, Pin F, Couch ME, Bonetto A, O'Connell TM. Development of a metabolic biomarker panel for the early detection of cancer cachexia. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 5–10.
9. Wang B, Zhang A, Klein J, Wang XH. Muscle derived exosome/miRNA-26a attenuates skeletal muscle wasting and cardiomyopathy in chronic kidney disease mice. J Cachexia Sarcopenia Muscle 2018;9:183–212, Abstract 3–18.
10. Ebhardt HA, Degen S, Tadini V, Schilb A, Johns N, Greig CA, Fearon KCH, Aebersold R, Jacobi C. Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study. J Cachexia Sarcopenia Muscle 2017;8:567–582.
11. Polge C, Cabantous S, Deval C, Claustre A, Hauvette A, Bouchenot C, Aniort J, Béchet D, Combaret L, Attaix D, Taillandier D. A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate. J Cachexia Sarcopenia Muscle 2018;9:183–212.
12. Ratnam NM, Peterson JM, Talbert EE, Ladner KJ, Rajasekera PV, Schmidt CR, Dillhoff ME, Swanson BJ, Haverick E, Kladney RD, Williams TM, Leone GW, Wang DJ, Guttridge DC. NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J Clin Invest 2017;127:3796–3809.
13. Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB. Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor extrinsic and intrinsic activities. Mol Cancer Ther 2016;3: pii: molcanther.0337.2016.
14. Saitoh M, Ishida J, Ebner N, Anker SD, von Haehling S. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e37:1–10.
15. Lodka D, Pahuja A, Geers-Knörr C, Scheibe RJ, Nowak M, Hamati J, Köhncke C, Purfürst B, Kanashova T, Schmidt S, Glass DJ, Morano I, Heuser A, Kraft T, Bassel-Duby R, Olson EN, Dittmar G, Sommer T, Fielitz J. Muscle RING-finger 2 and 3 maintain striated-muscle structure and function. J Cachexia Sarcopenia Muscle 2016;7:165–180.
16. Kowalski K, Archacki R, Archacka K, Stremińska W, Paciorek A, Gołąbek M, Ciemerych MA, Brzoska E. Stromal derived factor-1 and granulocyte-colony stimulating factor treatment improves regeneration of Pax7−/− mice skeletal muscles. J Cachexia Sarcopenia Muscle 2016;7:483–496.
17. Marino FE, Risbridger G, Gold E. Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle 2015;6:365–380.
18. Espinel-Bermúdez MC, Ramírez-García E, García-Peña C, Salvà-Casanovas A, Ruiz-Arregui L, Cárdenas-Bahena A, Sánchez-García S. Prevalence of sarcopenia in community-dwelling older people of Mexico City using the EGWSOP (European Working Group on Sarcopenia in Older People) diagnostic criteria. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e9:1–9.
19. Kamiya K, Hamazaki N, Matsuzawa R, Nozaki K, Tanaka S, Ichinosawa Y, Maekawa E, Noda C, Yamaoka-Tojo M, Matsunaga A, Masuda T, Ako J. Sarcopenia: prevalence and prognostic implications in elderly patients with cardiovascular disease. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e41:1–13.
20. Lønbro S, Farup J, Bentsen S, Voss T, Rittig N, Wang J, Ørskov M, Højris I, Mikkelsen UR. Lean body mass, muscle fibre size and muscle function in cancer patients during chemotherapy and 10 weeks exercise. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e26:1–8.
21. Dagan A, Sella T, Urban D, Bar Y, Onn A, Segal G. Low alanine transaminase is not associated with increased rate of mortality in patients with advanced lung cancer. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e16:1–8.
22. Souza NCS, Gonzalez MC, Martucci RB, Rodigues VD, Barroso de Pinho N, Avesani. Utility of phase angle as marker of low muscle mass, impaired muscle function and muscle quality in colorectal cancer patients. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 2–27.
23. O'Driscoll JM, Slee A, Sharma R. Body mass index mortality paradox in chronic kidney disease patients with suspected cardiac chest pain. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e10:1–8.
24. Aahlin EK, Irino T, Johns N, Brismar T, Nilsson M, Revhaug A, Lassen K. Body composition indices and tissue loss in patients with resectable gastric adenocarcinoma. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e13:1–7.
25. Patel J, Baruah D, Shahir K. A novel computed tomography method to detect normal from abnormal psoas muscle: a pilot feasibility study. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e14:1–6.
26. Szulc P, Wagner P, Chapurlat R. High risk of fall, fracture and rapid bone microstructure deterioration in men with poor physical performance—the prospective STRAMBO study. J Cachexia Sarcopenia Muscle 2017;8:999–1080, abstract 2–26.
27. Szulc P, Chapurlat R. Accelerated grip strength decline in older men with poor health and hormonal deficits—the prospective STRAMBO study. J Cachexia Sarcopenia Muscle 2016;7:43–128, Abstract 1–13.
28. Shafiee G, Heshmat R, Ostovar A, Keshtkar AA, Nabipour I, Soltani A, Larijani B. Development and validation of sarcopenia screening model for older people. J Cachexia Sarcopenia Muscle 2018;9: Abstract 2–09.
29. Priyadarshni S, Rahaman Z, Cabrera K, Dang S, Valencia W, Anam R, Mintzer MJ, Ruiz JG. Validating the Care Assessment Need (CAN) tool for frailty screening. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 2–13.
30. Beaudart C, Locquet M, Delandsheere L, Reginster JY, Bruyère O. The SarQoL®, a specific quality of life questionnaire for sarcopenia, is adapted to identify 1-year decrease in quality of life related to muscle function. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 2–58.
31. Barbosa-Silva TG, Mazocco L, Chagas P, Gonzalez MC. Results from the use of the SARC-F questionnaire associated with calf circumference as a sarcopenia screening tool in a Brazilian population. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 2–59.
32. Stimpson SA, Leonard MS, Clifton LG, Poole JC, Turner SM, Shearer TW, Remlinger KS, Clark RV, Hellerstein MK, Evans WJ. Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method. J Cachexia Sarcopenia Muscle 2013;4:217–223.
33. Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK, Foltz LA, Muppidi A, Alsina-Fernandez J, Barnard GC, Tang JX, Liu X, Mao X, Siegel R, Sloan JH, Mitchell PJ, Zhang BB, Gimeno RE, Shan B, Wu X. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 2017;23:1215–1219.
34. Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD, Cavanaugh CR, Nelson S, Huang C, Hunter MJ, Rangwala SM. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 2017;23:1150–1157.
35. Breit SN, Zhang HP, Manandhar R, Husaini Y, Lee-Ng M, Lebhar H, Marquis CP, Sainsbury A, Brown DA, Tsai VWW. The TGF-b family cytokine MIC-1/GDF15 has differential effects on lean mass in normal and obese mice. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 5–01.
36. Calder PC, Laviano A, Lonnqvist F, Muscaritoli M, Öhlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease (COPD): a randomized, double-blind controlled trial. J Cachexia Sarcopenia Muscle 2017;7.
37. Rodriguez AM, Braverman J, Aggarwal D, Friend J, Duus E. The experience of weight loss and its associated burden in patients with non-small cell lung cancer: results of an online survey. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2(), e18:1–15.
38. McClure R, Villani A. Mediterranean Diet attenuates risk of frailty and sarcopenia: new insights and future directions. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2, e45:1–17.
39. Cochrane SK, Chen SH, Fitzgerald JD, Dodson JA, Fielding RA, King AC, McDermott MM, Manini TM, Marsh AP, Newman AB, Pahor M, Tudor-Locke C, Ambrosius WT, Buford TW, LIFE Study Research Group. Association of accelerometry-measured physical activity and cardiovascular events in mobility-limited older adults: the life (lifestyle interventions and independence for elders) study. J Am Heart Assoc 2017;6.
40. Cesari M, Landi F, Calvani R, Cherubini A, Di Bari M, Kortebein P, Del Signore S, Le Lain R, Vellas B, Pahor M, Roubenoff R, Bernabei R, Marzetti E. SPRINTT Consortium. Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial. Aging Clin Exp Res 2017;29:81–88.
41. Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, Broccatelli M, Savera G, D'Elia M, Pahor M, Bernabei R, Landi F. SPRINTT Consortium. Physical activity and exercise as countermeasures to physical frailty and sarcopenia. Aging Clin Exp Res 2017;29:35–42.
42. Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE, Sabbah HN. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of Elamipretide. Circ Heart Fail 2017;10:e004389.
43. Kuang X, Sun Y, Wang Z, Zhou S, Liu H. A mitochondrial targeting tetrapeptide Bendavia protects lateral line hair cells from gentamicin exposure. J Appl Toxicol 201.
44. Serova M, Didry-Barca B, On S, Foucault AS, Raynal S, Veillet S, Dilda P, Lafont R. BIO103 a drug candidate for the treatment of muscle wasting disorders. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 8–09.
45. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–161.
46. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14:335–345.
47. Kanou M, Horie K, Nakamura K, Jimbo T, Sugiyama H, Yamana K. Efficacy of a novel selective androgen receptor modulator (TEI-SARM2) with once weekly dosing in rat unloaded muscle atrophy and Duchenne muscular dystrophy models. J Cachexia Sarcopenia Muscle 2017;8:999–1080, Abstract 8–07.
48. Singh A, Andreux PA, Blanco-Bose W, Aebischer P, Auwerx J, Rinsch C. Investigating the safety and impact on muscle mitochondria of orally administered Urolithin A: a randomized, double- blind, placebo controllen Phase 1 clinical trial in elderly. J Cachexia Sarcopenia Muscle 2018;9:183–212, Abstract 9–06.
49. Rygiel KA, Dodds RM, Patel HP, Syddall HE, Westbury LD, Granic A, Cooper C, Cliff J, Rocha MC, Turnbull DM, Sayer AA. Mitochondrial respiratory chain deficiency in older men and its relationship with muscle mass and performance. J Cachexia Sarcopenia Muscle Clinical Reports 2017;2, e37:1–11.
50. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2015;6:315–316.